Press Release

Modifying patients’ T-cells with mRNA to express a chimeric antigen receptor (rCAR-T therapy), a novel approach to treat myasthenia gravis and other autoimmune diseases. Gaithersburg, MD—June 22, 2023 – Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology. The study describes …

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity Read More »

Gaithersburg, MD—April 25, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of three world-renowned scientists and engineers as charter members of the company’s Scientific Advisory Board (SAB): Prof. Jennifer Elisseeff (Johns Hopkins University), Prof. Andrés García (Georgia Institute of Technology), and Prof. David …

Cartesian Therapeutics Announces Appointment of Three World-Renowned Scientists and Engineers as Charter Members of Company’s Scientific Advisory Board Read More »

Gaithersburg, MD—March 28, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of five internationally recognized experts in autoimmune diseases.  Cartesian’s appointments include distinguished physicians and scientists as leaders in clinical trials and medicine. “Cartesian is proud to have these prestigious, multidisciplinary advisors …

Cartesian Therapeutics Expands Clinical Advisory Board with Five Internationally Recognized Experts in Autoimmunity Read More »

Gaithersburg, MD—February 14, 2023 – Cartesian Therapeutics, a fully integrated biopharmaceutical company pioneering RNA cell therapy for autoimmune diseases and cancer, today announced the appointment of Christopher M. Jewell, PhD/MS as Chief Scientific Officer. Dr. Jewell’s predecessor, Michael Singer, MD, PhD, has been named Chairman of the Board and Chief Strategy Officer. Dr. Jewell is …

Cartesian Therapeutics Strengthens Research and Innovation Leadership with appointment of Professor Christopher M. Jewell as Chief Scientific Officer Read More »

⦁ First placebo-controlled study of an engineered cell therapy Gaithersburg, MD, January 31, 2023 – Cartesian Therapeutics, a fully integrated, clinical-stage biotechnology company pioneering RNA cell therapies for autoimmune diseases and cancer, has dosed the first participant in its Phase 2b randomized controlled trial (RCT) for generalized myasthenia gravis (MG), an autoimmune disorder that causes …

Cartesian Therapeutics Announces Dosing of First Participant in a Phase 2b Randomized Clinical Trial for Generalized Myasthenia Gravis Read More »

– Data Presentation Today at 14th Myasthenia Gravis Foundation of America International Conference on Myasthenia and Related Disorders in Miami – GAITHERSBURG, Md., May 10, 2022  – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, will present late-breaking interim data from its Phase 1/2a clinical trial of Descartes-08 in patients …

Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis Read More »

Descartes-25 engineered to deliver a combination of synergistically active anti-myeloma therapies directly to tumor microenvironment Product generated from Company’s Part 1271-compliant Master Cell Bank of human umbilical cord Mesenchymal Stem Cells Fifth IND in the five years since Cartesian was founded Gaithersburg, Md., January 25, 2022 – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company …

Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma Read More »

Gaithersburg, Md., Dec. 14, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the appointment of five internationally recognized Senior Advisors to support its growing clinical pipeline for autoimmune, respiratory, and inflammatory diseases.  Cartesian’s new appointments include distinguished physicians, scientists, professors, and industry experts …

Cartesian Therapeutics Adds Five Internationally Recognized Experts to Board of Advisors Read More »

Former CMO Metin Kurtoglu, M.D., Ph.D., appointed as the Company’s first Chief Operating Officer Cartesian expands cGMP manufacturing facility to support growing clinical pipeline Gaithersburg, Md., Sept. 28, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the hire of Miloš Miljković, M.D., as …

Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer Read More »

In cohort of three patients intended to test safety, all patients showed full-class improvement in the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification and substantial improvement in Myasthenia Gravis Composite scale. Descartes-08 was well tolerated in all three patients Gaithersburg, MD, August 24, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering …

Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis Read More »